Heng Ma
Beijing, 100730, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
Journal: Clinical nuclear medicine
Published: November 05, 2024
The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Journal: Theranostics
Published: May 26, 2023
Clinicopathological analysis of patients with molecularly confirmed stage I adult granulosa cell tumors and prediction of recurrence.
Journal: Gynecologic oncology
Published: March 20, 2023
Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma.
Journal: Frontiers in immunology
Published: August 25, 2022
Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma.
Journal: Cell death and differentiation
Published: July 08, 2022
Correction: Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Journal: BMC cancer
Published: May 31, 2022
Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.
Journal: Frontiers in immunology
Published: May 12, 2022
Oxidation States Regulation of Cobalt Active Sites through Crystal Surface Engineering for Enhanced Polysulfide Conversion in Lithium-Sulfur Batteries.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 23, 2022
Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node-Negative, p53-Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
Journal: Archives of pathology & laboratory medicine
Published: March 03, 2022
Identification and validation of TNFRSF4 as a high-profile biomarker for prognosis and immunomodulation in endometrial carcinoma.
Journal: BMC cancer
Published: January 08, 2022
Showing 1-12 of 12
Last Updated: 09/26/2026